CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: Addressing Barriers to Their Optimal Use

Share

Program Content

  • CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: Addressing Barriers to Their Optimal Use
    CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: Addressing Barriers to Their Optimal Use
    Patient Simulation
    Congratulations: You achieved a completion on 04/09/2022
    View Activity

Faculty

cover img faculity

Julia LaBarbera, MSN, RN, AGACNP-BC

Nurse Practitioner
Division of Hematology/Oncology
Department of Medicine
University of California, Los Angeles
Santa Monica, California